FDA Grades Itself Highly In Reports On Safety Of Imported Products And Marketed Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
As Congressional markups of user fee bills looms, the agency describes actions it has taken to protect the international supply chain in its Global Engagement report; another report notes the REMS and drug safety studies it has mandated under its postmarket drug safety program.
You may also be interested in...
U.S. FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data
It is going to take time for the public and policymakers to get comfortable with the idea of U.S. FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.
FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data
It is going to take time for the public and policymakers to get comfortable with the idea of FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.
FDA’s Latest Communication Project Is Grant Opportunity For Non-profits
The agency is offering a modest $200,000 grant to piggyback on efforts by non-profit groups to “foster better understanding of the work of CDER.”